Kineret®, Enbrel®, Remicade® and company: Recombinant drugs in rheumatoid arthritis;Kineret®, Enbrel®, Remicade® und co.: Rekombinante wirkstoffe bei rheumatoider arthritis

Pharmazie in Unserer Zeit

Volumn 32, Issue 5, 2003, Pages 376-383

  Zündorf, Ilse ^a   Dingermann, Theodor ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; ETANERCEPT; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SIALOGLYCOPROTEIN;

ARTICLE; B LYMPHOCYTE; HUMAN; NONHUMAN; PATHOGENESIS; RECOMBINANT DNA TECHNOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 17044448719     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200300036     Document Type: Article

References (12)

1. Produktmonografie Kineret® (Anakinra), Amgen GmbH.
2. Hannum, C.H. et al.: Interieukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336-340 (1990).
3. Carter, D.B. et al.: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344: 633-638 (1990).
4. Eisenberg, S.P. et al.: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 341-346 (1990).
5. Heller, R.A., Song, K., Onasch M.A., Fischer, W.H., Chang, D., Ringold, G.M.: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. PNAS 87: 6151-6155 (1990).
6. Produktmonografie Enbrel® (Etanercept), WYETH Pharma GmbH.
7. Produktmonografie Remicade® (Infliximab), ESSEX PHARMA GmbH.
8. Köhler, G., Milstein, C.: Continuous cultures of fused cells secreting antibody of predefined specifity. Nature 256: 495-497 (1975).
9. Knight, D.M. et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol 30: 1443-1453 (1993).
10. Lorenz, H.-M., Kalden, J.R.: Neue Therapieentwicklungen in der Rheumatoiden Arthritis. Z. Rheumatol. 60: 326-332 (2001).
11. Wilder, R.L: Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 Suppl. 2: ii96-99 (2002).
12. Bolon, B. et al.: Osteoprotegerin, an Endogenous Antiosteoclast Factor for Protecting Bone in Rheumatoid Arthritis. Arthritis & Rheumatism 46: 3121-3135 (2002).